Expression and relevance of the G protein-gated K\(^+\) channel in the mouse ventricle

Allison Anderson\(^1\), Kanchan Kulkarni\(^2\), Ezequiel Marron Fernandez de Velasco\(^3\), Nicholas Carlblom\(^4\), Zhilian Xia\(^1\), Atsushi Nakano\(^3\), Kirill A. Martemyanov\(^4\), Elena G. Tolkacheva\(^2\) & Kevin Wickman\(^1\)

The atrial G protein-gated inwardly rectifying K\(^+\) (GIRK) channel is a critical mediator of parasympathetic influence on cardiac physiology. Here, we probed the details and relevance of the GIRK channel in mouse ventricle. mRNAs for the atrial GIRK channel subunits (GIRK1, GIRK4), M2 muscarinic receptor (M\(_2\)R), and RGS6, a negative regulator of atrial GIRK-dependent signaling, were detected in mouse ventricle at relatively low levels. The cholinergic agonist carbachol (CCh) activated small GIRK currents in adult wild-type ventricular myocytes that exhibited relatively slow kinetics and low CCh sensitivity; these currents were absent in ventricular myocytes from \(\text{Girk1}^{-/-}\) or \(\text{Girk4}^{-/-}\) mice. While loss of GIRK channels attenuated the CCh-induced shortening of action potential duration and suppression of ventricular myocyte excitability, selective ablation of GIRK channels in ventricle had no effect on heart rate, heart rate variability, or electrocardiogram parameters at baseline or after CCh injection. Additionally, loss of ventricular GIRK channels did not impact susceptibility to ventricular arrhythmias. These data suggest that the mouse ventricular GIRK channel is a GIRK1/GIRK4 heteromer, and show that while it contributes to the cholinergic suppression of ventricular myocyte excitability, this influence does not substantially impact cardiac physiology or ventricular arrhythmogenesis in the mouse.

Increased output of the parasympathetic branch of the autonomic nervous system leads to the slowing of heart rate (HR) and an increase in heart rate variability (HRV), an indicator of beat-to-beat fluctuations in HR\(^1,2\). Abnormal parasympathetic regulation of cardiac output has been linked to multiple cardiac disorders, including atrial fibrillation (AF), atrioventricular (AV) block, heart failure, and sudden cardiac death\(^3\)–\(^7\). The parasympathetic influence on the heart involves acetylcholine (ACh) acting on sino-atrial nodal (SAN) and atrio-ventricular nodal (AVN) cells, as well as atrial myocytes\(^8\)–\(^10\). ACh binds to M\(_2\) muscarinic receptors (M\(_2\)R) on these cells, initiating a branched intracellular signaling pathway mediated by inhibitory (Gi/o) G proteins, culminating in the activation of the K\(^+\) channel I\(_{\text{KACH}}\), as well as the suppression of the cAMP/PKA-dependent cation-selective ion channel (HCN1) and voltage-gated Ca\(^{2+}\) channels\(^11\)–\(^14\).

The atrial I\(_{\text{KACH}}\) channel is a GIRK channel consisting of GIRK1 and GIRK4 subunits, in 1:1 stoichiometry\(^15,16\). I\(_{\text{KACH}}\) is gated by G protein G\(_{\beta\gamma}\) subunits liberated following M\(_2\)R activation\(^17,18\). Genetic ablation of either \(\text{Girk1}\) or \(\text{Girk4}\) in mice eliminated the I\(_{\text{KACH}}\) conductance in neonatal atrial myocytes, and yielded a modest increase in HR and decrease in HRV at baseline in adult animals\(^19,20\). Additionally, HR and HRV responses to ACh and CCh were diminished in isolated hearts from mice lacking GIRK1 or GIRK4\(^19\)–\(^22\).

While the parasympathetic impact on cardiac function is typically ascribed to its influence on the atria, SA node, and AV node, parasympathetic innervation of ventricular tissue is also evident in mammals\(^20\). In addition, profound effects of vagal nerve stimulation (VNS) on ventricular physiology have been noted in several species\(^23\). For example, chronic VNS altered the electrophysiological properties of the heart and reduced susceptibility to ventricular arrhythmias in rats\(^24\). Additionally, ACh shortened action potential duration (APD) in human ventricular myocytes, in an atropine-sensitive manner\(^25\). This effect has been attributed to the activation of a GIRK channel...
channel23,26–28. Consistent with this premise, the ACh-induced decrease in APD and effective refractory period (ERP) in rat papillary muscle was blocked by the non-selective GIRK channel blocker tertiapin, and ACh triggered hyperpolarization and a reduction in APD in right ventricle recordings from wild-type but not Girk4−/− mice29.

In addition, a mutation in the human GIRK4/KCNJ5 gene underlies a congenital form of Long QT Syndrome (LQTS13), a ventricular repolarization disorder associated with arrhythmia, syncope, and sudden death28,30.

While available evidence supports the contention that a GIRK channel contributes to the cholinergic influence on ventricular physiology, critical details remain unclear. Here, we examined the expression in mouse ventricle of genes implicated in atrial IKACh-dependent signaling, and evaluated the impact of gene ablation on cholinergic signaling in ventricular myocytes. We present functional evidence that the GIRK channel in ventricular myocytes is a GIRK1/GIRK4 heteromer, and that it mediates the impact of cholinergic signaling on APD and excitability of these cells. We also probed the physiological impact of ventricular GIRK-dependent signaling using a novel ventricle-specific Girk1−/− mouse line. Our findings reveal that, despite the contribution of GIRK channels to the CCh-dependent acceleration of repolarization and decrease in ventricular myocyte excitability, ventricular GIRK-dependent signaling does not exert a significant impact on HR, HRV, or susceptibility to ventricular arrhythmias in mice.

Results

Expression of IKACh-dependent signaling pathway elements in mouse atria and ventricle. Expression of key elements of the atrial M2R-IKACh signaling pathway, including GIRK1, GIRK4, M2R, and RGS6, has been detected in ventricular tissue from many mammalian species23,26,28,31–33. A study in the rat heart revealed higher expression in atria than ventricle for GIRK1, GIRK4, and RGS634. We sought to confirm these findings in the mouse by comparing the expression levels of these targets, as well as M2R, in the atria and ventricle of adult mice using quantitative RT-PCR. We found that GIRK1, GIRK4, M2R, and RGS6 mRNAs were all present in mouse ventricular tissue, but that the levels of all targets were lower (4–10-fold) than those found in mouse atrial tissue (Fig. 1).

Evidence of a GIRK1/GIRK4 heteromer in mouse ventricular myocytes. Previous work suggests that a GIRK4-containing GIRK channel is present in rodent ventricle26,28. While GIRK1/GIRK4 heteromeric channels are thought to mediate the atrial IKACh conductance, some evidence suggests that GIRK4 homomeric channels may contribute as well26,37. To assess the relative contributions of GIRK1 and GIRK4 to the GIRK channel activity in ventricle, we measured whole-cell currents induced by the non–selective cholinergic agonist carbachol (CCh) in ventricular myocytes from wild-type mice, and from mice lacking GIRK1 or GIRK4. Ventricular myocytes express a prominent constitutive K+ current (I_K1) that masks the ACh/CCh-induced GIRK current under normal whole-cell recording conditions, due to K+ accumulation and/or depletion38. As such, we included a low concentration of Ba2+ (5 μM) in our bath solution to selectively suppress I_K1, while preserving any potential GIRK channel activity. Indeed, 5 μM Ba2+ did not suppress the CCh-induced GIRK current in wild-type SAN cells; indeed, currents were slightly larger in the presence Ba2+ (Supplementary Fig. S1).

CCh (100 μM) evoked reliable currents in ventricular myocytes from adult wild-type mice, but not in myocytes from Girk1−/− or Girk4−/− mice (Fig. 2a,b). Since GIRK1 is unable to form functional homomeric channels26,39–42, this observation supports the contention that GIRK1 and GIRK4 assemble to form the GIRK channel in mouse ventricular myocytes. The peak density of the CCh-induced GIRK current was ~5–10 fold

---

**Figure 1.** Expression of IKACh-dependent signaling elements in mouse atria and ventricle. mRNA levels of GIRK1 (t14 = 9.4, ***P < 0.001), GIRK4 (t14 = 21.2, ***P < 0.001), M2R (t13 = 18.6, ***P < 0.001), and RGS6 (t14 = 6.7, ***P < 0.001), and in atria and ventricle from adult C57BL/6J mice, compared using an unpaired Student’s t-test. mRNA levels of each target were normalized to the level of GAPDH mRNA measured in each sample. Ventricular mRNA levels for each target was normalized to the level present in atrial samples (n = 7–8 samples per tissue, per target).
smaller in ventricular myocytes, however, as compared to currents reported in SAN cells. Additionally, the CCh-induced current activation and deactivation kinetics were significantly slower for the ventricular GIRK channel as compared to the atrial GIRK channel (Fig. 2c,d). Furthermore, the ventricular GIRK current was more than an order of magnitude less sensitive to CCh (EC_{50} = 4.8 \pm 0.6 \mu M; Fig. 2e) than the SAN cell GIRK current (EC_{50} = 0.25 \pm 0.03 \mu M)43, reminiscent of the lower ACh sensitivity of the GIRK conductance in human ventricular myocytes as compared to atrial myocytes44.

**Influence of RGS6 on GIRK-dependent signaling in ventricular myocytes.** The M_{2R}-I_{KACh} signaling pathway in atrial myocytes and SAN cells is negatively regulated by Regulator of G protein Signaling 6 (RGS6)22,32,43,45. Indeed, in SAN cells and atrial myocytes from mice lacking RGS6, GIRK currents evoked by CCh exhibited slower deactivation kinetics and an increased sensitivity to CCh2,43. To test whether ventricular GIRK-dependent signaling is negatively regulated by RGS6, we compared CCh-induced GIRK currents in ventricular myocytes from adult wild-type and Rgs6^{−/−} mice. Current densities were slightly, but significantly, larger in ventricular myocytes from Rgs6^{−/−} mice as compared to wild-type controls (Fig. 2a,b). No effect of Rgs6 ablation, however, was seen on activation (Fig. 2c) or deactivation (Fig. 2d) kinetics of the CCh-induced, ventricular GIRK current. Moreover, the EC_{50} for CCh-induced activation of the GIRK current was comparable in ventricular myocytes from wild-type and Rgs6^{−/−} mice (Fig. 2e). Thus, the impact of RGS6 on ventricular GIRK-dependent signaling is limited to a modest negative regulation of peak current density.

**Influence of GIRK channels on ventricular myocyte APD and excitability.** To test whether I_{KACh} modulates ventricular myocyte excitability and repolarization, we evaluated the change in rheobase and APD induced by CCh (100 \mu M) in ventricular myocytes from wild-type and Girk4^{−/−} mice. The CCh-induced decrease

---

**Figure 2.** Carbachol-induced GIRK currents in adult mouse ventricular myocytes. (a) Whole-cell currents (V_{hold} = −70 mV) evoked by carbachol (CCh, 100 \mu M) in a high-K+ bath solution (containing 5 \mu M BaCl_{2}) in adult ventricular myocytes from wild-type, Girk1^{−/−}, Girk4^{−/−}, and Rgs6^{−/−} mice. Scale: 0.1 nA/10 s. (b) Summary of maximal CCh-induced current density in adult ventricular myocytes from wild-type (n = 28 cells/6 mice), Girk1^{−/−} (n = 23 cells/4 mice), Girk4^{−/−} (n = 21 cells/4 mice), and Rgs6^{−/−} mice (n = 24 cells/6 mice); open symbols overlapping the bars denote individual data points. One-way ANOVA analysis revealed an effect of genotype on CCh-induced current density (F_{3,92} = 110.6, P < 0.001). Symbols: ***, P < 0.001, respectively, vs. wild-type. (c,d) Summary of activation (c; t_{44} = 0.7, P = 0.51) and deactivation (d); t_{44} = 1.1, P = 0.28) kinetics for the CCh-induced current in ventricular myocytes from wild-type (n = 25 cells/6 mice) and Rgs6^{−/−} mice (n = 21 cells/6 mice), compared across genotypes using an unpaired Student’s t-test. (e) Summary of EC_{50} values derived from concentration-response experiments for the CCh-induced current in adult ventricular myocytes from wild-type vs. Rgs6^{−/−} mice. The EC_{50} for current activation by CCh did not differ between wild-type (4.8 ± 0.6 \mu M, n = 11 cells/4 mice) and Rgs6^{−/−} (4.9 ± 0.4 \mu M, n = 19 cells/4 mice) ventricular myocytes, as determined using an unpaired Student’s t-test (t_{28} = 0.20, P = 0.84).
in ventricular myocyte excitability (increase in rheobase) was larger in ventricular myocytes from wild-type than
\( \text{Girk4}^{-/-} \) mice (Fig. 3a). And, although there was no significant difference in the CCh-induced shortening of
APD 20, APD 50, and APD 70 between ventricular myocytes from wild-type and \( \text{Girk4}^{-/-} \) mice (Fig. 3b–e), the
CCh-induced decrease in APD 90 was blunted in ventricular myocytes from \( \text{Girk4}^{-/-} \) mice (Fig. 3f). Thus, GIRK
channels contribute to the cholinergic regulation of excitability and repolarization of adult mouse ventricular
myocytes.

**Generation and characterization of mice lacking GIRK channels in ventricle.** To probe the
impact of ventricular GIRK channel on cardiac physiology, we crossed a conditional \( \text{Girk1} \) knockout mouse
(\( \text{Girk1fl/fl} \)) with a ventricle-specific Cre driver line (MLC2VCre)\(^47,48\). We first verified the ventricular specific-
ity of Cre-dependent gene ablation conferred by the MLC2VCre driver line using a Cre-dependent fluorescent
reporter mouse line (Fig. 4a,b). We next evaluated the functional impact and cell specificity of \( \text{Girk1} \) ablation by
measuring CCh-induced whole-cell currents in SAN cells and ventricular myocytes from MLC2VCre(−):\( \text{Girk1}^{+/+} \)
and MLC2VCre(−):\( \text{Girk1}^{0/0} \) mice. CCh-induced current density in adult ventricular myocytes from
MLC2VCre(−):\( \text{Girk1}^{0/0} \) mice was significantly smaller than responses measured in ventricular myocytes from
MLC2VCre(−):\( \text{Girk1}^{+/+} \) littermates (Fig. 4c,d). We observed no difference, however, in CCh-induced current

---

Figure 3. GIRK channel contribution to the cholinergic regulation of mouse ventricular myocyte repolarization
and excitability. (a) Change in rheobase evoked by CCh (100 μM) in adult wild-type (n = 19 cells/5 mice) and
\( \text{Girk4}^{-/-} \) (n = 26 cells/6 mice) ventricular myocytes, compared using an unpaired Student’s t-test (\( t_{43} = 5.1,***P < 0.001 \)). (b) Action potentials evoked by current injection in wild-type and \( \text{Girk4}^{-/-} \) ventricular
myocytes, at baseline (solid line) and in the presence of CCh (100 μM, dashed line). Scale: 20 mV/25 ms.
(c–f) Summary of the percentage change in APD 20 (\( t_{29} = 0.37, P = 0.72 \)), APD 50 (\( t_{29} = 0.38, P = 0.71 \)), APD 70
(\( t_{29} = 0.97, P = 0.34 \)), and APD 90 (\( t_{29} = 3.5, **P < 0.01 \)) evoked by CCh in wild-type (n = 17 cells/6 mice) and
\( \text{Girk4}^{-/-} \) (n = 14 cells/5 mice) ventricular myocytes, compared using an unpaired Student’s t-test.
density in SAN cells from adult MLC2VCre(−):Girk1fl/fl and MLC2VCre(+)::Girk1fl/fl mice (Fig. 4e). Thus, GIRK channel activity is selectively suppressed in ventricular myocytes from MLC2VCre(+)::Girk1fl/fl mice.

Impact of ventricle-specific GIRK channel ablation on cardiac physiology. To discern the impact of ventricle-specific GIRK channel ablation on cardiac physiology, we evaluated electrocardiogram (ECG) recordings from anesthetized MLC2VCre(−):Girk1fl/fl and MLC2VCre(+)::Girk1fl/fl mice, as well as wild-type and constitutive Girk4−/− mice. We measured HR (Fig. 5) and HRV (Figs 6 and 7), as well as specific waveform parameters (PR, QT, and QTc intervals; Supplementary Table 1), at baseline and following systemic administration of CCh (1.0 mg/kg i.p.). At baseline, HR was slightly higher in Girk4−/− mice relative to wild-type controls,
but this difference did not reach the level of statistical significance (Fig. 5a–c). Similarly, no significant difference in baseline HR was observed in MLC2VCre(+)::Girk1fl/fl mice relative to MLC2VCre(−)::Girk1fl/fl controls (Fig. 5d). As expected, CCh decreased HR in wild-type mice, and this effect was significantly smaller in Girk4−/− mice (Fig. 5a–c). In contrast, CCh-induced bradycardia was comparable in MLC2VCre(+)::Girk1fl/fl and MLC2VCre(−)::Girk1fl/fl mice (Fig. 5d). Arrhythmic events, defined as instances of AV block or tachycardic episodes, were also quantified before and after CCh injection (Supplementary Fig. S2). While no arrhythmic events were observed at baseline for any genotype, wild-type mice exhibited more arrhythmic events than Girk4−/− mice after CCh injection. Both MLC2VCre(+)::Girk1fl/fl mice and MLC2VCre(−)::Girk1fl/fl mice exhibited a similar frequency of arrhythmic events after CCh injection.

Figure 5. HR analysis of constitutive and ventricle-specific Girk−/− mice. (a,b) Segments of ECG recordings from anesthetized wild-type (a) and Girk4−/− (b) mice, at baseline and after injection of CCh (1.0 mg/kg i.p.). Scale: 1 s. (c) Summary of HR data at baseline and after injection of CCh for wild-type (n = 12) and Girk4−/− (n = 13) mice. Two-way ANOVA analysis revealed an interaction between genotype and treatment (F1,23 = 54.8, P < 0.001). Symbols: ***P < 0.01 and 0.001, respectively, vs. baseline (within genotype); **P < 0.01 vs. wild-type (within treatment). (d) Summary of HR data at baseline and after injection of CCh for MLC2VCre(+)::Girk1fl/fl (n = 13) and MLC2VCre(−):Girk1fl/fl (n = 12) littermates. There was a significant main effect of treatment (F1,23 = 173.1, P < 0.001), but no main effect of genotype (F1,23 = 3.6, P = 0.070), or interaction between genotype and treatment (F1,23 = 0.09, P = 0.77). Symbols: ***P < 0.001 vs. baseline (within genotype).

Figure 6. Time-domain HRV analysis of constitutive and ventricle-specific Girk−/− mice. (a,b) RR tachograms for anesthetized wild-type (a) and Girk4−/− (b) mice, at baseline and following injection of CCh (1.0 mg/kg i.p.). Scale: 10 s. (c) Summary of RMSSD data at baseline and following injection of CCh for wild-type (n = 12) and Girk4−/− (n = 13) mice. Two-way ANOVA analysis revealed an interaction between genotype and treatment (F1,23 = 158.7, P < 0.001). Symbols: ***P < 0.001 vs. baseline (within genotype); ### P < 0.001 vs. wild-type (within treatment). (d) Summary of RMSSD data at baseline and following injection of CCh for MLC2VCre(−):Girk1fl/fl (n = 13) and MLC2VCre(+)::Girk1fl/fl (n = 12) littermates. There was a significant main effect of treatment (F1,23 = 96.3, P < 0.001), but no main effect of genotype (F1,23 = 3.2, P = 0.087) or interaction between genotype and treatment (F1,23 = 0.66, P = 0.43). Symbols: ***P < 0.001 vs. baseline (within genotype).
Figure 7. Frequency domain HRV analysis in constitutive and ventricle-specific Girk<sup>−/−</sup> mice. (a) Power in the VLF (<0.4 Hz) range at baseline and following injection of CCh (1.0 mg/kg i.p.). Two-way ANOVA analysis revealed an interaction between genotype and treatment ($F_{1,23} = 36.3, P < 0.001$) for wild-type (n = 12) and Girk<sup>−/−</sup> (n = 13) mice (left panel). While main effects of treatment ($F_{1,23} = 51.0, P < 0.001$) and genotype ($F_{1,23} = 13.77, P < 0.01$) were observed for MLC2VCre(−):Girk1<sup>fl/fl</sup> (n = 13) and MLC2VCre(+):Girk1<sup>fl/fl</sup> (n = 12) mice (right panel), there was no interaction between genotype and treatment ($F_{1,23} = 0.01, P = 0.90$). Symbols: ***$P < 0.001$ vs. baseline (within genotype); ###$P < 0.001$ vs. wild-type (within treatment). (b) Power in the LF (0.4–1.5 Hz) range at baseline and following injection of CCh (1.0 mg/kg i.p.). Two-way ANOVA analysis revealed an interaction between genotype and treatment ($F_{1,23} = 41.6, P < 0.001$) for wild-type and Girk<sup>−/−</sup> mice (left panel). While main effects of treatment ($F_{1,23} = 113.1, P < 0.001$) and genotype ($F_{1,23} = 8.8, P < 0.01$) were observed for MLC2VCre(−):Girk1<sup>fl/fl</sup> and MLC2VCre(+):Girk1<sup>fl/fl</sup> mice (right panel), there was no interaction between genotype and treatment ($F_{1,23} = 0.02, P = 0.88$). Symbols: ***$P < 0.001$ vs. baseline
We next evaluated HRV, examining the root mean square of successive differences (RMSSD) in R-R interval before and after CCh injection. While baseline RMSSD in Girk4−/− mice was slightly lower in comparison to wild-type mice, this difference did not reach the level of statistical significance (Fig. 6a–c). Consistent with published data22, the CCh-induced increased in RMSSD was significantly blunted in Girk4−/− mice relative to wild-type controls (Fig. 6c). MLC2VCre(−):Girk1fl/fl and MLC2VCre(+):Girk1fl/fl mice displayed comparable RMSSD values, both prior to and after CCh injection (Fig. 6c).

Frequency domain analysis can offer a more sensitive measure of the relative contributions of the sympathetic and parasympathetic branches of the autonomic nervous system to HRV49. While power in the VLF range (<0.4 Hz) at baseline did not differ between wild-type and Girk4−/− mice, CCh increased VLF power in wild-type but not Girk4−/− mice (Fig. 7a, left). In the LF range (0.4–1.5 Hz), Girk4−/− mice exhibited reduced power relative to wild-type controls at baseline and, in contrast to wild-type mice, a lack of increase induced by CCh (Fig. 7b, left). In the HF range (1.5–5.0 Hz), we observed no difference between wild-type and Girk4−/− mice at baseline. Interestingly, CCh administration decreased power in this frequency range in wild-type mice, but not Girk4−/− mice (Fig. 7c, left). No difference in power in VLF, LF, and HF domains was observed between MLC2VCre(+):Girk1fl/fl and MLC2VCre(−):Girk1fl/fl mice, either at baseline or after CCh administration (Fig. 7a–c, right).

With respect to key parameters of the ECG waveform (Supplementary Table 1), no significant genotype differences were observed for PR and QT intervals at baseline. CCh significantly prolonged both the PR and QT intervals in wild-type mice, and this effect was blunted in Girk4−/− mice. PR and QT intervals were also prolonged in MLC2VCre(+):Girk1fl/fl and MLC2VCre(−):Girk1fl/fl mice after CCh administration, but there was no difference between genotypes. We also evaluated the corrected QT (QTc) interval, a measure that can account for the influence of HR on the QT interval50, using a variation of the human QT correction formula that assumes a typical RR interval for a conscious mouse under normal conditions (100 ms). We observed no difference in QTc interval between wild-type and Girk4−/− mice, or MLC2VCre(+):Girk1fl/fl or MLC2VCre(−):Girk1fl/fl mice, at baseline. Interestingly, while CCh administration had no effect on QTc interval in wild-type mice, it lengthened this interval in Girk4−/− mice. QTc interval was not prolonged after CCh injection, however, in either MLC2VCre(+):Girk1fl/fl or MLC2VCre(−):Girk1fl/fl mice.

Impact of ventricle-specific GIRK channel ablation on pacing-induced ventricular arrhythmia.
To investigate the contribution of the ventricular GIRK channel to ventricular arrhythmogenesis, isolated hearts from MLC2VCre(+):Girk1fl/fl and MLC2VCre(−):Girk1fl/fl mice, as well as wild-type and constitutive Girk4−/− mice, were subjected to burst pacing in the absence and presence of CCh to discern differences in susceptibility to ventricular tachycardia (VT) or fibrillation (VF) (Fig. 8a). There was no significant difference in the incidence of pacing-induced VT/VF at baseline between wild-type and Girk4−/− hearts (Fig. 8b, left). Similarly, hearts from MLC2VCre(+):Girk1fl/fl and MLC2VCre(−):Girk1fl/fl mice did not differ in the incidence of VT/VF in response to pacing stimuli at baseline. After CCh perfusion, there was, again, no significant difference in incidence of pacing-induced VT/VF between wild-type and Girk4−/− hearts (Fig. 8b, right). Likewise, no difference was observed in the incidence of pacing-induced VT/VF between MLC2VCre(+):Girk1fl/fl and MLC2VCre(−):Girk1fl/fl hearts. Collectively, these observations suggest that loss of the ventricular GIRK channel does not impact susceptibility to pacing-induced ventricular arrhythmias.

Discussion
In this study, we present evidence that GIRK channel found in adult mouse ventricular myocytes is, like the channel described previously in atrial myocytes and SAN cells, a GIRQ1/GIRK4 heteromultimeric channel. Nevertheless, the GIRK current in ventricular myocytes exhibited several properties that differed from the GIRK current described previously in atrial myocytes and SAN cells33,40. Notably, the ventricular GIRK current was smaller and less sensitive to CCh. The differences in GIRK conductance between atrial and ventricular myocytes could be due to increased expression and/or influence of a negative regulator of GIRK-dependent signaling in ventricle. Our data suggest that increased ventricular expression or influence of RGS6, however, does not explain the functional differences between the mouse atrial and ventricular GIRK conductance. Indeed, RGS6 mRNA levels were substantially lower in ventricle than in atria. Moreover, Rgs6 ablation did not enhance the CCh sensitivity or alter the kinetics of the ventricular GIRK current. It is possible that other RGS proteins account for the differences observed between in atrial and ventricular GIRK-dependent signaling in the mouse heart. Alternatively, elements of the GIRK-dependent signaling pathway may be compartmentalized in distinct fashion in the atria and ventricle, or additional positive and/or negative regulatory elements that impact I_{GIRK}β-dependent signaling remain to be discovered.

A recent study reported that the ACh-induced shortening of ventricular APD_{90} was diminished in isolated hearts from Girk4−/− mice, suggesting that a GIRK4-containing GIRK channel facilitates ventricular repolarization in the mouse heart29. Consistent with this premise, we observed a significant impact of Girk4 ablation on the
CCh-induced shortening of APD<sub>90</sub> in isolated ventricular myocytes from adult mice. Our efforts in isolated ventricular myocytes also revealed that \( \text{Girk4} \) ablation attenuates the CCh-induced decrease in ventricular myocyte excitability. These results support our contention that the GIRK channel in ventricular myocytes contributes to the cholinergic regulation of ventricular myocyte APD and excitability.

\( \text{I}_{\text{KAC}} \) is a critical downstream mediator of parasympathetic effects on atrial physiology and HR regulation. Previous studies with ECG telemetry and isolated mouse hearts have shown that a loss of \( \text{I}_{\text{KAC}} \) correlates with altered baseline measures and diminished responses to pharmacologic manipulations that enhance or mimic parasympathetic input to the heart\(^{19-22} \). Here, we replicated several reported observations in \( \text{Girk4}^{−/−} \) mice, including the attenuation of CCh-induced bradycardia. While we did not see a significant baseline tachycardia in \( \text{Girk4}^{−/−} \) mice in this study, this may reflect an influence of anesthesia. We additionally observed evidence of diminished HRV at baseline (LF), and after CCh administration (RMSSD, VLF, and LF), in \( \text{Girk4}^{−/−} \) mice. Our parallel evaluation of mice lacking GIRK channels selectively in ventricle indicate that most, if not all, of the cardiac phenotypes reported in constitutive \( \text{Girk1}^{−/−} \) or \( \text{Girk4}^{−/−} \) mice are attributable to a loss of atrial \( \text{I}_{\text{KAC}} \). Surprisingly, we found that CCh decreased power in the HF domain in wild-type mice, but not in \( \text{Girk4}^{−/−} \) mice. As fluctuations in HR due to respiration contribute to power in the HF range\(^{51} \), our observation could reflect a contribution of a GIRK4-containing GIRK channel to the cholinergic regulation of respiration. The CCh-induced decrease in HF power was not significant in MLC2VCre\((-\text{:Girk1}^{fl/fl}, \text{MLC2VCre}(+)\text{:Girk4}^{fl/fl} \) mice, however, suggesting that this parameter may not be a reliable indicator of the GIRK channel contribution to HRV in this frequency range.

Despite the fact that GIRK channels contribute to the inhibitory influence of CCh on ventricular myocytes, we did not see an obvious impact of ventricular GIRK channel ablation on QT or QTC intervals, at baseline or following CCh injection. It should be noted that previous attempts to model long-QT syndrome in mice have not reliably yielded mice with prolonged QT intervals\(^{52} \). For example, mice lacking \( \text{KvLQT1} \), the gene associated with LQT1 in large mammals, do not consistently display prolonged QT intervals\(^{52} \). We also cannot exclude the possibility that the influence of ventricular GIRK channel becomes more relevant in pathological conditions such as myocardial infarction or sympathetic stress. We did see a surprising prolongation of the QTC interval after CCh administration in \( \text{Girk4}^{−/−} \) mice that was not seen in wild-type controls. While this observation may reflect a failure of the QT correction to adequately compensate for the impact of HR on QT interval or a limitation of this approach in mice under anesthesia\(^{53,54} \), the finding is also consistent with the possibility that CCh modulates

**Figure 8.** Susceptibility to pacing-induced ventricular arrhythmias in constitutive and ventricle-specific \( \text{Girk}^{−/−} \) mice. (a) Recording of a VT episode after infusion of CCh (3 μM) and burst pacing of the left ventricle. Scale: 0.5 V/0.2 s. (b) Summary of the number of mice exhibiting VT/VF episodes after burst pacing of the left ventricle at baseline (left) and after CCh perfusion (right). Fisher’s exact test revealed no differences in the occurrence of VT/VF episodes between wild-type and \( \text{Girk4}^{−/−} \) mice, either at baseline \((P = 1.0)\) or after CCh administration \((P = 1.0)\). We did not observe any incidents of VT/VF in MLC2VCre\((-\text{:Girk1}^{fl/fl}, \text{MLC2VCre}(+)\text{:Girk4}^{fl/fl} \) mice, either at baseline or after CCh administration.
another effector that exerts an opposing influence from the GIRK channel on the QT interval. Importantly, since MLC2VCre(+/+)Girk1fl/fl and MLC2VCre(−/−)Girk1fl/fl mice exhibited similar QT and QTc intervals at baseline and after CCh administration, the selective prolongation of QTc interval in Girk4−/− mice presumably reflects an influence of GIRK channels outside of the ventricle.

Girk4−/−-dependent signaling has been linked to a variety of atrial rhythm disorders55-57. Both genetic ablation of Girk4 and pharmacological inhibition of GIRK channels can restore normal cardiac rhythm in multiple genetic models of supraventricular arrhythmia55,56. For example, genetic ablation of Girk4 in mouse models of sick sinus syndrome and AV block reduces the number of ACh-induced arrhythmic episodes in these mice56. Additionally, fewer arrhythmic events were observed in Girk4−/− mice treated with CCh as compared to wild-type controls (this study), and Girk4−/− mice were resistant to pacing-induced AF55. Studies in human AF patients further implicate IKACh in supraventricular arrhythmogenesis. Atrial myocytes from human AF patients displayed both a significant reduction in IKACh expression and an attenuation of CCh-induced shortening of atrial AP56. CCh-induced IKACh currents were also smaller in atrial myocytes from AF patients, whereas constitutive GIRK channel activity was elevated58-60. Remodeling involving IKACh has also been observed in a “tachy-paced” dog model, where atrial tachycardia increased basal IKACh channel activity63; this adaptation correlated with a decrease in ERP and an increase in AF duration. Collectively, these studies highlight the therapeutic potential associated with blocking or suppressing atrial IKACh in multiple distinct atrial arrhythmias.

IKACh antagonists have been proposed for use in the treatment of AF and other supraventricular rhythm disorders65,66,67-69. Recently, a novel family of direct-acting, small molecule activators and inhibitors of GIRK channels has been identified, members of which act selectively on GIRK1-containing GIRK channels such as IKACh. While a direct-acting IKACh antagonist could prove useful in the treatment of atrial rhythm disorders, suppressing GIRK channel activity in the ventricle could pose a significant risk. We did not, however, observe a difference in susceptibility to pacing-induced ventricular arrhythmias in either the constitutive or ventricle-specific GIRK channel ablation models, arguing that a loss of ventricular GIRK channel does not predispose to ventricular arrhythmias. However, given the noted differences in the ionic currents underlying ventricular repolarization in mice and humans63, further studies are needed to determine whether inhibition of the human ventricular GIRK channel is also without effect. Nonetheless, our data support the contention that targeting IKACh for atrial arrhythmias, via with selective inhibitors or genetic approaches, may constitute a safe alternative to existing anti-arrhythmic therapies that predispose patients to fatal ventricular disorders64.

Methods

Animals. All experimental procedures involving mice were approved by the Institutional Animal Care and Use Committee of the University of Minnesota, and were conducted in accordance with guidelines set by the National Institute of Health. The generation of Girk1−/−, Girk4−/−, Rgs6−/−, and Girk1fl/fl mice was described previously18,20,65,66. Girk1fl/fl mice were crossed with MLC2VCre(+/+) mice to generate the MLC2VCre(Girk1fl/fl) line. B6.Cg-Gi(Rosa)26 Sor +/−(Ai14-tdTomato)33/31+ (Ai14-tdTomato) reporter mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and crossed with MLC2VCre(+) mice. Mice were group-housed on a 12-h light/dark cycle, and given free access to food and water and were used for experiments at age 8–12 wk.

Quantitative RT-PCR. Total RNA was isolated from freshly isolated atrial and ventricular tissue samples from adult C57BL/6j mice using the RNasy fibrous tissue kit (Qiagen; Germantown, MD), according to manufacturer recommendations. Reverse transcription was performed using iScript cDNA Synthesis Kit (Bio-Rad Laboratories; Hercules, CA). Quantitative PCR was performed in a StepOnePlus Real Time PCR System (Applied Biosystems; Foster City, CA), with the Fast SYBR Green Master Mix (ThermoFisher Scientific; Waltham, MA). The following amplification program was used: 95 °C/20 s followed by 40 cycles of 95 °C/3 s, 60 °C/30 s. Intron-spanning primer pairs were as follows: M2R: 5′-CCATGTTGAGGATGCTTT-3′ (forward) and 5′-CTTCAGGTTGGGTCAAAG-3′ (reverse); GIRK1: 5′-AAGCTCTACTCTAGTTCGG-3′ (forward) and 5′-CTCCAGTCCAGTTGCTAAG-3′ (reverse); GIRK4: 5′-GAGTTGGAGTGGTGCATA-3′ (forward) and 5′-GACCTCTCGATCCATGTAAG-3′ (reverse); RGS6: 5′-CTGACACTTGGCTGCAGTTG-3′ (forward) and 5′-GAGAATGCTGGCTGGATGG-3′ (reverse). The specificity of the GIRK1, GIRK4, and RGS6 reactions was assessed with a melting curve at the end of the program, and confirmed using samples from Girk1−/−, Girk4−/−, and Rgs6−/− mice, respectively. Samples were tested in duplicate, and the average of replicates was used in the final data analysis. GAPDH (Mm_Gapd_2_SG QuantiTect primers; Qiagen) was used as internal control in each sample.

Cell culture.SAN cells and ventricular myocytes were isolated as described15,68. Mice were injected intra-peritoneally (i.p.) with heparin (250 U) and then anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg). To obtain SAN cells, hearts were excised into Tyrode’s solution (in mM): 140 NaCl, 5.4 KCl, 1.2 KH2PO4, 1.0 MgCl2, 1.8 CaCl2, 5.55 glucose, 5 HEPEs, pH 7.4 with NaOH. SAN-containing tissue was excised into a modified Tyrode’s solution containing (in mM): 140 NaCl, 5.4 KCl, 1.2 KH2PO4, 0.2 CaCl2, 50 taurine, 18.5 glucose, 5 HEPEs, 0.1% BSA, pH 6.9 with NaOH, with elastase (0.3 mg/mL, Worthington Biochemical Corp., Lakewood, NJ) and collagenase II (0.21 mg/mL; Sigma Aldrich, St. Louis, MO). SAN tissue was digested at 37 °C for 30 min and then washed three times in a solution containing (in mM): 100 L-glutamic acid/potassium salt, 10 L-aspartic acid/potassium salt, 25 KCl, 10 KH2PO4, 2 MgSO4, 20 taurine, 5 creatine, 0.5 EGTA, 20 glucose, 5 HEPEs, 0.1% BSA, pH 7.2 with KOH. SAN tissue was then triturated and plated on laminin-coated coverslips (25 μg/mL) and used within 8 h.
Ventricular myocytes were extracted by excising hearts into ice-cold cell isolation buffer (in mM): 118 NaCl, 4.8 KCl, 25 HEPES, 1.2 KH₂PO₄, 1.2 MgSO₄, 11 glucose, 30 taurine, 10 2,3-butanedione monoxime, pH 7.4 (with NaOH). The aorta was subsequently cannulated and hearts were then retrogradely perfused using a Langendorff apparatus with warm cell isolation buffer supplemented with collagenase II (620 U/μL; Worthington Biochemical Corp.). After a 10 min digestion, the heart was taken off the cannula and the atria were removed. The ventricles were cut into pieces and triturated. Samples were then transferred to a stop buffer consisting of cell isolation buffer supplemented with 2.5% BSA, 0.1 mM CaCl₂, 5% FBS; where CaCl₂ was added in three, 5 min increments to reach a final CaCl₂ concentration of 1.6 mM. The cell suspension was then transferred to media consisting of M199, 0.2% BSA, 26.2 mM sodium bicarbonate, 25 mM HEPES, insulin-transferin-sodium-selenite solution (1X), 5% FBS, penicillinic (1,000 U), streptomycin (1 mg), pH 7.4 (with NaOH); and plated on laminin-coated coverslips (25μg/mL) and used within 8 h.

**Whole-cell electrophysiology.** Coverslips containing adult SAN cells or ventricular myocytes were transferred to a perfusion chamber and electrophysiological recordings were conducted as described. SAN cells were identified as thin, striated cells with capacitance values between 20–40 pF. Ventricular myocytes were identified as quiescent, rod-shaped cells with capacitance values ranging from 100–250 pF. Whole-cell currents and voltages were measured with hardware (Axopatch-700B amplifier, Digidata 1440A) and software (pCLAMP v. 10 from Molecular Devices, Sunnyvale, CA). All currents were low-pass filtered at 0.1 kHz, sampled at 5 kHz, and stored on computer hard disk for analysis. The liquid-junction potential, predicted to be −17 mV using IPCalc software (Molecular Devices), was not corrected. CCh-induced currents were measured at a holding potential of −70 mV. Borosilicate patch pipettes were filled with (in mM): 130 K-gluc, 2 MgCl₂, 1.1 EGTA, 5 HEPES, 2 Na₃ATP, 5 phosphocreatine, and 0.3 Na-GTP, pH 7.2 (with KOH). Whole-cell access was achieved in a low-K⁺ bath solution consisting of (in mM): 130 NaCl, 5.4 KCl, 1 CaCl₂, 1 MgCl₂, 5.5 glucose, 5 HEPES/NaOH, pH 7.4. A high-K⁺ bath solution (+/- CCh) consisting of (in mM): 120 NaCl, 25 KCl, 1 CaCl₂, 1 MgCl₂, 5.5 glucose, 5 HEPES/NaOH, pH 7.4 was applied via ValvuLink 8.2 rapid perfusion system (AutoMate Scientific, Berkeley, CA). Activation and deactivation time constants were extracted from appropriate regions of current traces, which were fit with a 1-term Boltzmann equation. Rheobase was evaluated in current-clamp mode in low-K⁺ bath solution by injecting increasing steps (5 pA/500 ms) of depolarizing current, starting at 0 pA, until an action potential spike was elicited. APD₂₀, APD₅₀, APD₇₀, and APD₉₀ were measured from the average of 10 spikes elicited by injecting a supra-threshold current (1 nA/5 ms) into the cell. The % change in APD and rheobase after CCh perfusion was measured as with the follows: (baseline – post-CCh/baseline) × 100. Only those experiments in which the access resistances were stable and low (<20 Ω) were included in the final analysis.

**Microscopy.** Hearts were fixed with 4% paraformaldehyde in PBS at 4 °C for 16–24 h, transferred to a 10% sucrose/PBS solution at 4 °C for 4 h, and then transferred to a solution of 30% sucrose/PBS solution at 4 °C for at least 48 h. 20 μm thick slices were cut by cryostat at −20 °C and slices were mounted and stained with ProLong Gold Antifade reagent with DAPI (ThermoFisher Scientific; Waltham, MA). Fluorescent images were captured with an Olympus BX51W1 upright microscope with Disk Spinning Unit, using a 2X objective and digital CCD camera (C10600-10B, Hamamatsu Photonic System Corp; Bridgewater, NJ). Images were processed with Metamorph Advanced 7.7.7.0 (Molecular Devices).

**In vivo ECG recordings.** Mice were anesthetized with 1.5% isoflurane supplemented with an air mixture of 40% O₂/60% N₂ to sustain stable HR. Platinum needle ECG electrodes connected to an IX-ECG-12 recorder (iWorx; Dover, NH) were placed subcutaneously into each limb. Baseline HR was recorded for 10 min, at which point CCh (1.0 mg/kg i.p.) was administered. HR and HRV analysis was performed on 1-min bins of stable recording from minutes 9–10 (baseline) and 15–16 min (post-CCh), using Kubios HRV 3.02 software. Artifact detection/correction was utilized to reduce the impact of ectopic and skipped beats (either AV block or RR intervals which differ from the neighboring RR intervals by over 25%) on HR and HRV analysis. The frequency bands for HRV analysis were defined as very low frequency (VLF), <0.4; low frequency (LF), 0.4–1.5 Hz; and high frequency (HF), 1.5–5.0 Hz, using a 120 s window with a 50% overlap for Fast Fourier Transform spectrum analysis using Welch’s periodogram method. Arrhythmic events were defined as instances of AV block (P wave with no corresponding QRS complex) and/or instances of tachycardia (at least 3–5 beats). PR and QT intervals were analyzed from the average of 100 cycles from either lead I or lead II during these segments, using LabScribe v3 software, only from recordings where the noise level was sufficiently low to clearly delineate the beginning and end of the indicated waveform deflections. The QT interval was corrected for changes in RR interval using the following formula: QTc = SQRT[QT/(RR/100)]

**Ex vivo burst pacing.** Hearts were excised and submerged in cardioplegic solution (in mM): 280 glucose, 13.44 KCl, 12.6 NaHCO₃, and 34mannitol. The aorta was subsequently cannulated and retrogradely perfused with warm (37±1°C), oxygenated Tyrode’s (in mM): 130 NaCl, 1.8 CaCl₂, 4 KCl, 1.0 MgCl₂, 1.2 NaH₂PO₄, 24 NaHCO₃, 5.5 glucose, pH 7.4. Once hearts had been allowed to stabilize for 10 min, burst pacing at decreasing basic cycle lengths (BCL) (100 BCL down to 10 BCL, step-size 10) was applied 3 times to determine susceptibility to ventricular tachycardia (VT) or fibrillation (VF) at baseline via a stimulating electrode placed at the base of the left ventricle. Once the protocol was finished, 3 μM CCh was perfused into the hearts. After a 2–5 min stabilization period, the burst pacing protocol was run once again. Analysis was done using LabChart v7.3.8 software (ADInstruments; Colorado Springs, Colorado), where occurrences of VT lasting at least 7–8 beats, were tallied before and after CCh infusion.
Statistical analysis. All data are presented as the mean ± SEM. Statistical analyses were performed using Prism 5 (GraphPad Software, Inc.; La Jolla, CA) software. Male and female mice were used in all studies, and groups were balanced for sex. Data were analyzed with Student's two-tailed t-test (unpaired and paired), Fisher's exact test, 1-way ANOVA, and 2-way ANOVA with repeated measures, as appropriate. For studies involving 2-way ANOVA analysis, only the interaction is reported if one was detected. The Bonferroni multiple comparison post hoc test was used following 1-way or 2-way ANOVA analyses, if justified. The level of significance was set at P < 0.05.

Data availability. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References
1. Lombardi, F. & Stein, P. K. Origin of heart rate variability and turbulence: an appraisal of autonomic modulation of cardiovascular function. Front. Physiol. 2, 85, https://doi.org/10.3389/fphys.2011.00095 (2011).
2. Draghici, A. E. & Taylor, J. A. The physiological basis and measurement of heart rate variability in humans. J. Physiol. Anthropol. 35, 22, https://doi.org/10.1186/s40101-016-0113-7 (2016).
3. Bigger, J. T. Jr et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 85, 164–171 (1992).
4. Schwartz, P. J. The autonomic nervous system and sudden death. Europ. Heart J. 19(Suppl F), F72–80 (1998).
5. La Rovere, M. T. et al. Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. J. Am. Coll. Cardiol. 53, 193–199 (2009).
6. Alboni, P., Holz, A. & Brigonne, M. Vagal mediated atrioventricular block: pathophysiology and diagnosis. Heart 99, 904–908 (2013).
7. Munger, T. M., Wu, L. Q. & Shen, W. K. Atrial fibrillation. Heart Fail. Rev. 10, 1500–1506 (2013).
8. Stewart, A., Huang, J. & Fisher, R. A. RGS proteins in heart: brakes on the vagus. J. Gen. Physiol. 192, 434–446 (2010).
9. Krapivinsky, G. & Clapham, D. E. Ion channel regulation by G proteins. Physiol. Rev. 85, 865–885 (1995).
10. Wickman, K. & Clapham, D. E. Structural characterization of the mouse Girk channel. J. Biol. Chem. 277, 5271–5278 (1998).
11. Logothetis, D. E., Kurachi, Y., Galper, J., Neer, E. J. & Clapham, D. E. The beta gamma subunits of GTP-binding proteins activate the muscarinic K+ channel in heart. Nature 325, 321–326 (1987).
12. Wickman, K. et al. Recombinant G-protein beta gamma subunits activate the muscarinic-gated atrial potassium channel. Nature 368, 255–257 (1994).
13. Wickman, K., Nemec, J., Gendler, S. J. & Clapham, D. E. Abnormal heart rate regulation in GIRK4 knockout mice. Neuron 20, 103–114 (1998).
14. Bettahi, I., Marker, C. L., Roman, M. I. & Wickman, K. Contribution of the Kir3.1 subunit to the muscarinic-gated atrial Kᵢ,AKCh channel. J. Biol. Chem. 277, 48282–48288 (2002).
15. Krapivinsky, G. et al. The G-protein-gated atrial Kᵢ,AKCh, is a heteromultimer of two inwardly rectifying K⁺-channel proteins. Nature 374, 135–141 (1995).
16. Carey, K., Krapivinsky, G., Krapivinsky, L. & Clapham, D. E. Number and stoichiometry of subunits in the native atrial G-protein. Heart Fail. Rev. 16, 109–127 (2011).
17. Stewart, A., Huang, J. & Fisher, R. A. The G protein-activated (GIRK) current (I(K(ACh))). Evidence for functional homomeric GIRK4 channels. J. Biol. Chem. 276, 28873–28880 (2001).
18. Wickman, K. et al. Essential role of the M₂R-RGS6-IKACh pathway in controlling intrinsic heart rate variability. PloS One 8, e76973 (2013).
19. Lee, S. W. et al. Chronic cyclic vagus nerve stimulation has beneficial electrophysiological effects on healthy hearts in the absence of autonomic imbalance. Physiol. Rep. 4, 9, https://doi.org/10.14814/phy2.12786 (2016).
20. Komori, S., Sato, R., Nagasawa, K. & Hayakawa, H. Activation of inwardly rectifying potassium channels by muscarinic receptor-linked G protein in isolated human ventricular myocytes. J. Membr. Biol. 157, 71–81 (1997).
21. Dobrzynski, H. et al. Identification of a Kir3.4 mutation in congenital long QT syndrome. J. Med. Genet. 38, 95, https://doi.org/10.1136/jmedgenet.38.1.95 (2001).
22. Bigger, J. T. Jr. et al. The autonomic nervous system and sudden death. Circulation 85, 164–171 (1992).
23. Dong, H., Zuo, J., Wu, Z., Pu, W. T. & Clapham, D. E. Evidence that the M₂R-RGS6-IKACh pathway controls intrinsic heart rate variability. J. Am. Coll. Cardiol. 63, 175–184 (2014).
24. Wang, F. et al. The phenotype characteristics of type 13 long QT syndrome with mutation in KCNJ5 (Kir3.4-G387R). Heart Rhythm 10, 1300–1306 (2013).
25. Dong, H., Zuo, J., Wu, Z. & Clapham, D. E. Essential characterization of the mouse Girk genes. Gene 284, 241–250 (2002).
26. Yang, Y. et al. Identification of a Kir3.4 mutation in congenital long QT syndrome. J. Hum. Genet. 86, 872–880 (2010).
27. Liang, B. et al. G-protein-coupled inward rectifier potassium current contributes to ventricular repolarization. Cardiovasc. Res. 101, 175–184 (2014).
28. Wang, F. et al. The phenotype characteristics of type 13 long QT syndrome with mutation in KCNJ5 (Kir3.4-G387R). Heart Rhythm 10, 1300–1306 (2013).
29. Wickman, K., Pu, W. T. & Clapham, D. E. Structural characterization of the mouse Girk genes. Gene 284, 241–250 (2002).
30. Yang, Y. et al. GIRK mediates myocardial cell apoptosis and cardiomyopathy caused by doxorubicin. Cancer Res. 73, 1662–1667 (2013).
31. McGrath, M. F. & de Bold, A. J. Transcriptional analysis of the mammalian heart with special reference to its endocrine function. BMC Genomics 10, 254, https://doi.org/10.1186/1471-2164-10-254 (2009).
32. Kovoor, P. et al. Evaluation of the role of I(K(ACh)) in atrial fibrillation using a mouse knockout model. J. Am. Coll. Cardiol. 37, 2136–2143 (2001).
33. Carey, K. & Clapham, D. E. Identification of native atrial G-protein-regulated inwardly rectifying K⁺ (GIRK4) channel homomultimers. J. Biol. Chem. 273, 27409–27404 (1998).
34. Bender, K. et al. Overexpression of monomeric and multimeric GIRK4 subunits in rat atrial myocytes reduces fast desensitization and reduces inward rectification of muscarinic K⁺ current (I(K(ACh))). Evidence for functional homomeric GIRK4 channels. J. Biol. Chem. 276, 28873–28880 (2001).
35. Beckmann, C. et al. G protein-activated (GIRK) current in rat ventricular myocytes is masked by constitutive inward rectifier current (I(K1)). Cell. Physiol. Biochem. 21, 259–268 (2008).
42. Ma, D.

43. Wydeven, N., Posokhova, E., Xia, Z., Martemyanov, K. A. & Wickman, K. RGS6, but not RGS4, is the dominant regulator of G protein signaling (RGS) modulator of the parasympathetic regulation of mouse heart rate. J. Biol. Chem. 274, 2571–2582 (1999).

44. Ma, D. et al. Diverse trafficking patterns due to multiple traffic motifs in G protein-activated inwardly rectifying potassium channels from brain and heart. Neuron 33, 715–729 (2002).

45. Koumi, S. & Wasserstrom, J. A. Acetylcholine-sensitive muscarinic K+ channel subunits. J. Biol. Chem. 274, 2571–2582 (1999).

46. de Velasco, M. F., Carlbom, E., Xia, N., Xia, Z. & Wickman, K. Suppression of inhibitory G protein signaling in forebrain pyramidal neurons triggers plasticity of glutamatergic neurotransmission in the nucleus accumbens core. Neuropharmacology 117, 33–40 (2017).

47. Chen, J. et al. Selective requirement of myosin light chain 2v in embryonic heart function. J. Biol. Chem. 273, 1252–1256 (1998).

48. Chen, J., Kubalak, S. W. & Chien, K. R. Ventricular muscle-restricted targeting of the RXXalpha gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. Development 125, 1943–1949 (1998).

49. Gehrmann, J. et al. Phenotypic screening for heart rate variability in the mouse. Am. J. Physiol. Heart Circ. Physiol. 279, H733–740 (2000).

50. Mitchell, G. F., Jeron, A. & Koren, G. Measurement of heart rate and Q-T interval in the conscious mouse. Am. J. Physiol. 274, H747–751 (1998).

51. Tsai, M. L., Chen, C. C., Yeh, C. J., Chou, L. M. & Cheng, C. H. Frequency ranges of heart rate variability related to autonomic nerve activity in the mouse. Clin. Exp. Hypertens. 34, 182–190 (2012).

52. Salama, G. & London, B. Mouse models of long QT syndrome. J. Physiol. 578, 43–53 (2007).

53. Boukens, B. J., Rivaud, M. R., Rentschler, S. & Coronel, R. Misinterpretation of the mouse ECG: 'musing the waves of Mus musculus'. J. Physiol. 592, 4613–4626 (2014).

54. Roussel, J. et al. The complex QT/RR relationship in mice. Sci. Rep. 6, 23588, https://doi.org/10.1038/srep23588 (2016).

55. Mesirca, P. et al. Cardiac arrhythmia induced by genetic silencing of ‘funny’ (f) channels is rescued by GIRK4 inactivation. Nat. Commun. 5, 4664, https://doi.org/10.1038/ncomms4664 (2014).

56. Mesirca, P. et al. G protein-gated IK,ACH channels as therapeutic targets for treatment of sick sinus syndrome and heart block. Proc. Natl. Acad. Sci. USA 113, E932–941 (2016).

57. Li, N. et al. Adenosine-induced atrial fibrillation: localized reentrant drivers in lateral right atria due to heterogeneous expression of adenosine A1 receptors and GIRK4 subunits in the human heart. Circulation 134, 486–498 (2016).

58. Dobrev, D. & et al. Molecular basis of downregulation of G-protein–coupled inward rectifying K(+) current (IK,ACH) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced IK,ACH and muscarinic receptor-mediated shortening of action potentials. Circulation 104, 2551–2557 (2001).

59. Dobrev, D. et al. The G protein-gated potassium current IK,ACH is constitutively active in patients with chronic atrial fibrillation. Circulation 112, 3697–3706 (2005).

60. Dobrev, D. et al. Human inward rectifier potassium channels in chronic and postoperative atrial fibrillation. Cardiovasc. Res. 54, 397–404 (2002).

61. Voigt, N. et al. Changes in IK,ACH single-channel activity with atrial tachycardia remodelling in canine atrial cardiomyocytes. Cardiovasc. Res. 77, 35–43 (2008).

62. Tanaka, H. & Hashimoto, N. A multiple ion channel blocker, NIP-142, for the treatment of atrial fibrillation. Cardiovasc. Drug Rev. 25, 342–356 (2007).

63. Bhave, G., Lonergan, D., Chaufer, B. A. & Denton, J. S. Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities. Future Med. Chem. 2, 757–774 (2010).

64. Li, D., Sun, H. & Levesque, P. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety. Cardiovasc. Hematol. Agents Med. Chem. 7, 64–75 (2009).

65. Kaufmann, K. et al. ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays anti-platelet properties in mice. ACS Chem. Neurosci. 4, 1278–1286 (2013).

66. Ven, W. et al. Discovery of ‘molecular switches’ within a GIRK4-activating scaffold that afford selective GIRK inhibitors. Bioorg. Med. Chem. Lett. 23, 4562–4566 (2013).

67. Ramos-Hunter, S. J. et al. Discovery and SAR of a novel series of GIRK1/2 and GIRK1/4 activators. Bioorg. Med. Chem. Lett. 23, 5195–5198 (2013).

68. Prins, K. W., Asp, M. L., Zhang, H., Wang, W. & Metzger, J. M. Microtubule-mediated misregulation of junctophilin-2 underlies t-tubule disruptions and calcium mishandling in mdx mice. JACC Basic Transl. Sci. 1, 122–130 (2016).

69. Tarvainen, M. P., Niskanen, J. P., Lipponen, J. A., Ranta-Aho, P. O. & Karjalainen, P. A. Kubios HRV-heart rate variability analysis software. Comput. Methods Programs Biomed. 113, 210–220 (2014).

Acknowledgements
This work was supported by grants from the National Institutes of Health to KW and KAM (HL105550), AA (HL139090), AN (HL124503), and ET (HL128790).

Author Contributions
A.A., K.A.M. and K.W. designed the overall scope of the study. A.A., K.K., E.M.Fd.V., N.C., Z.X., A.N., E.T. and K.W. were responsible for experimental design, execution of experiments, and/or data analysis. A.A. and K.W. wrote the manuscript. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-19719-x.

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
